Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Portfolio Pulse from
Adagene Inc. will present updated clinical data from its Phase 1b/2 study of Muzastotug in combination with KEYTRUDA® for colorectal cancer at the ASCO GI Cancers Symposium.
January 21, 2025 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adagene Inc. is set to announce updated data from its study of Muzastotug in combination with KEYTRUDA® for colorectal cancer, which could influence investor sentiment and stock price.
The announcement of updated clinical data at a major symposium could positively impact Adagene's stock price as it may indicate progress in their drug development, attracting investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90